A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs PF 06865571 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 21 May 2018 Status changed from active, no longer recruiting to completed.
    • 04 May 2018 Planned End Date changed from 11 Apr 2018 to 30 May 2018.
    • 04 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top